Customized TULSA-PRO Ablation Registry

 Data from patients who have undergone or are currently undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their regular clinical care will be entered into this patient registry. The registry will shed light on actual outcomes of procedure safety and effectiveness and help researchers determine how a patient's quality of life changes over the course of their lifespan and follow-up visits.



General Requirements:

• Male
• >18 years old
• Candidate for TULSA-PRO treatment
• willing and able to sign the Informed Consent form

NCT05001477

ExoDx Prostate Evaluation in Active Surveillance Patient Population

This observational study aims to investigate whether patients with prostate cancer undergoing active monitoring can benefit from the ExoDx Prostate test when deciding whether to undergo a biopsy.



General Requirements:

• Male, 45+ years of age diagnosed with low-grade prostate cancer and currently monitoring with a urologist/provider. If you do not have a provider at the moment you can be seen with Dr Kella.

NCT05572099

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

 The patients in this multi-center, prospective, observational trial who are receiving ORGOVYX treatment. The objective of this study is to produce practical evidence regarding the safety and efficacy of ORGOVYX in patients with prostate cancer receiving standard clinical care, as well as the clinical course both during and after therapy with ORGOVYX.



General Requirements:

• Patients who are diagnosed with prostate cancer and initiating treatment with ORGOVYX at the time of enrollment or within 1 month prior to enrollment and who remain on treatment at enrollment
• Patients who are willing and able to complete PRO assessments during the study
• Patients who have reviewed and signed the informed consent form (ICF)

NCT05467176

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate (REPLACE-CV)

This study compares the risk of major adverse cardiovascular events (MACE) for relugolix and leuprolide acetate in a randomized fashion. Patients ages 18 and older who are getting relugolix or leuprolide acetate for their prostate cancer or as an adjuvant to radiation therapy with a treatment plan to be on androgen deprivation therapy (ADT) for at least one year will have clinical and cardiovascular risk factor data collected as part of this study.

General Requirements:

• Confirmed diagnosis of prostate cancer
• Patients with ≥ 3 of the following cardiovascular risk factors:
• Age (≥ 55 years of age);
• High blood pressure
• Diabetes
• High cholesterol levels
• Current cigarette use, defined as smoking within the year prior to the screening visit
• Family history of cardiovascular disease, defined as a heart attack or stroke, carotid procedures
• Patients must not be participating or intending to participate in an interventional therapeutic study.

NCT05605964